Comparing LAI and Oral Antipsychotic Options: Expert Discussions with Schizophrenia Case Reports
Released On
July 31, 2023
Expires On
October 31, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Psychiatry
Topics
Schizophrenia
Supported by educational grants from Alkermes, Inc., Indivior, Inc., and Teva Pharmaceuticals.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of psychiatrists and psychiatric NP/PA’s.
Program Overview
On average, long-acting injectable antipsychotics (LAIAs) are often initiated late in adults with schizophrenia, despite evidence supporting early use. Leslie Citrome, MD, MPH, John Lauriello, MD, and Amber Hoberg PMHNP-BC discuss the latest guideline recommendations, benefits to early intervention services (EIS), barriers to initiating treatment with LAIAs, and compare efficacy and safety of LAIAs and oral medications in schizophrenia treatment. These data and considerations are then applied to real-world patient case studies as Drs Citrome and Lauriello, and Pyschiatric NP Amber R. Hoberg determine the appropriate therapy for each patient, including their candidacy for treatment with LAIAs and how to switch from oral to LAI medication.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Examine data comparing the efficacy of LAIAs and oral medications.
- Analyze the clinical trial data and unique considerations of available LAIAs.
- Implement early integration of LAIA therapies in appropriate patients.
Faculty
John Lauriello, MD
Professor and Chair of Psychiatry
and Human Behavior
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania
Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry
and Behavioral Sciences
New York Medical College
Valhalla, New York
Amber R Hoberg, PMHNP-BC
Psychiatric Nurse Practitioner
Morning Star Family Medicine
San Antonio, Texas
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Disclosures of Financial Relationships
The CME Institute adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). Any individuals in a position to control the content of a continuing education activity, including faculty, content developers, reviewers, staff, and others, are required to disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The CME Institute has mitigated all relevant conflicts of interest prior to the commencement of the activity. None of the individuals involved in the content have relevant financial relationships with ineligible companies except the following:
Ms. Hoberg is a consultant for Teva, Neurocrine. Has received speaker honoraria from Teva, Neurocrine, Intracellular Therapies, Avanir, Acadia, Axsome, and BioXcel. She has also received advisory board fees from Teva, Acadia, Intracellular Therapies, Sunovion and Neurocrine.
Dr. Lauriello is a consultant for Karuna Pharmaceuticals, Avanir Therapeutics, Teva and BioXcel.
Dr. Citrome is a consultant for AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva. He is a stockshare holder for Bristol-Myers Squibb, Eli Lilly, J & J, Merck and has stock options for Reviva. He has received speaker honoraia from AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, and Teva. He has received publishing/royalty income from Taylor & Francis, Wiley, International Journal of Clinical Practice, UpToDate , Springer Healthcare, Elsevier.
None of the other planners, reviewers, and CME Institute staff for this educational activity have relevant financial relationships with ineligible companies to disclose. All relevant financial relationships have been mitigated.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The CME Institute of Physicians Postgraduate Press, Inc. requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions please contact: [email protected] .